Govt Job: For IMTech Doctoral Degree in Pharma Job | Salary Rs. 42,000 pm

Established in 1984, the Institute of Microbial Technology (IMTech) is one of the 37 national laboratories, 6 units, and 39 outreach centers of the Council of Scientific and Industrial Research.

Set-up to be a fore-runner in the niche domain of microbial biotechnology, the Institute in its initial years functioned from a start-up laboratory that provided a truly world-class R&D ambience in an area of over 10,000 sq. ft. to its researchers.

In September, 1989, upon completion of the permanent campus, the Institute shifted to occupy an area of about 47 acres, of which the labs covered 22 acres and the residential campus 25 acres.

Post :Senior Project Associate (01 post)

Project titled : “To Study the mechanism of action of spermidine in pathogenesis of Salmonella enterica, shigella flexneri and staphylococcus aureus.”

Project Code : MLP-0042

Essential Qualification :
(i) Master’s Degree in Natural or Agricultural Sciences/ MVSc or bachelor’s degree in Engineering or Technology or Medicine from a recognized University or equivalent; and

(ii) 4 years experience in Research and Development in Industrial and Academic Institutions or Science and Technology Organisations and Scientific activities and services.

OR
Doctoral Degree in Science / Engineering / Technology / Pharma / MD / MS from a recognized University or equivalent

Desirable : The Candidate with an expertise in genetic manipulation, knowledge in animal handling and experience in vivo studies and knowledge in cloning, over-expression and purification of protein is desirable.

Upper Age limit (years) – 40

Monthly Emoluments : Rs.42,000/- + HRA

ROLLING ADVT. NO. 04-02

Related Posts

  • Pharma
  • June 24, 2025
  • 58 views
Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). The drug is a specially designed anti-PD-1 monoclonal…

  • Pharma
  • June 24, 2025
  • 69 views
India’s herbal and ayurvedic OTC market set to outpace global growth

New Delhi: India’s herbal and ayurvedic OTC (over the counter) market is expected to grow at a CAGR of 6.5 per cent, from $69 million in 2025 to $118 million…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharma launches TEVIMBRA in India

India’s herbal and ayurvedic OTC market set to outpace global growth

India’s herbal and ayurvedic OTC market set to outpace global growth

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug